Travere Therapeutics (NASDAQ: TVTX) is a rare disease biopharmaceutical company that develops and commercializes treatments for serious kidney and metabolic disorders. Revenue comes from product sales of approved therapies, supplemented by milestone payments and royalties from licensing partners. The company's primary commercial product is FILSPARI (sparsentan), which received full FDA approval in September 2024 to slow kidney function decline in adults with primary IgA nephropathy (IgAN). FILSPARI is the only oral, once-daily, non-immunosuppressive therapy targeting two pathways of IgAN disease progression. A second program, pegtibatinase, is in a pivotal Phase 3 study (HARMONY) for homocystinuria (HCU), with enrollment restarted in Q1 2026 following a voluntary pause in September 2024. Travere also holds rights to sparsentan in markets outside Japan and parts of Asia, where Chugai Pharmaceutical holds exclusive rights following its acquisition of Renalys Pharma in Q4 2025. The company is incorporated in Delaware and operates in the United States and internationally.

Revenue model

Product sales of approved therapies (primarily FILSPARI), plus milestone payments and royalties from licensing agreements, including an Asian licensing deal with Chugai Pharmaceutical (formerly Renalys Pharma) that generated $10.2 million at closing in Q4 2025 and provides eligibility for future milestones and sales-linked consideration.

Products and services

FILSPARI (sparsentan): oral, once-daily endothelin-1 and angiotensin II dual antagonist, FDA fully approved September 2024 for IgAN; European Commission conditional marketing authorization granted April 2024 via partner CSL Vifor. Pegtibatinase: investigational enzyme replacement therapy for homocystinuria (HCU), in pivotal Phase 3 HARMONY Study with enrollment restarted Q1 2026.

Customers and end markets

Adult patients with rare kidney diseases (primary IgA nephropathy, focal segmental glomerulosclerosis, Alport syndrome) and metabolic disorders (homocystinuria). Prescribing physicians and healthcare payers are key access gatekeepers. Products are available in the United States; sparsentan also authorized in Europe via CSL Vifor and licensed in Japan, South Korea, and Taiwan via Chugai.

Value-chain role

Drug developer and commercial-stage biopharmaceutical company. Conducts clinical development, holds regulatory approvals, and commercializes products directly in the United States. Uses licensing and partnership structures for international markets.

Geographic exposure

Primary commercial market is the United States. Sparsentan has conditional marketing authorization in Europe (commercialized via CSL Vifor partnership). Exclusive licensing rights for Japan, South Korea, and Taiwan held by Chugai Pharmaceutical following Q4 2025 acquisition of Renalys.

Competitors

irbesartan (named active comparator in PROTECT Study)

Source: SEC 10-K, filed 2026-02-19

Industry: Pharmaceutical Preparations Peers: Agios Pharmaceuticals Inc Allogene Therapeutics Inc Iovance Biotherapeutics Inc Ironwood Pharmaceuticals Inc Lyell Immunopharma Inc Myriad Genetics Inc Novavax Inc Revolution Medicines Inc Recursion Pharmaceuticals Inc